Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

Brian I. Rini, MD
Published: Monday, Jul 02, 2018



Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Among the multiple combination immunotherapy studies that are currently ongoing in RCC, the tolerability profile of atezolizumab and bevacizumab is a distinguishing feature of this regimen, Rini says. In a presentation of patient-reported outcomes from the IMmotion151 at the 2018 ASCO Annual Meeting, various scales and instruments were used to measure this. Although there are no efficacy data to show differences in activity, there are differences in tolerability between the regimens.

Previously-reported findings from the IMmotion151 study showed that the combination reduced the risk of progression or death by 26% compared to sunitinib (Sutent) in patients with untreated PD-L1–positive metastatic RCC. The average time to deterioration of a patient was about 11 months, which corresponds with the progression-free survival, Rini says.


Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Among the multiple combination immunotherapy studies that are currently ongoing in RCC, the tolerability profile of atezolizumab and bevacizumab is a distinguishing feature of this regimen, Rini says. In a presentation of patient-reported outcomes from the IMmotion151 at the 2018 ASCO Annual Meeting, various scales and instruments were used to measure this. Although there are no efficacy data to show differences in activity, there are differences in tolerability between the regimens.

Previously-reported findings from the IMmotion151 study showed that the combination reduced the risk of progression or death by 26% compared to sunitinib (Sutent) in patients with untreated PD-L1–positive metastatic RCC. The average time to deterioration of a patient was about 11 months, which corresponds with the progression-free survival, Rini says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x